Antipyretics: Mechanisms of action and clinical use in fever suppression

被引:181
作者
Aronoff, DM
Neilson, EG
机构
[1] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Div Infect Dis, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA
[4] Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA
关键词
D O I
10.1016/S0002-9343(01)00834-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fever is a complex physiologic response triggered by infectious or aseptic stimuli. Elevations in body temperature occur when concentrations of prostaglandin E-2 (PGE(2)) increase within certain areas of the brain. These elevations alter the firing rate of neurons that control thermoregulation in the hypothalamus. Although fever benefits the nonspecific immune response to invading microorganisms, it is also viewed as a source of discomfort and is commonly suppressed with antipyretic medication. Antipyretics such as aspirin have been widely used since the late 19th century, but the mechanisms by which they relieve fever have only been characterized in the last few decades. It is now clear that most antipyretics work by inhibiting the enzyme cyclooxygenase and reducing the levels of PGE, within the hypothalamus. Recently, other mechanisms of action for antipyretic drugs have been suggested, including their ability to reduce proinflammatory mediators, enhance anti-inflammatory signals at sites of injury, or boost antipyretic messages within the brain. Although the complex biologic actions of antipyretic agents are better understood, the indications for their clinical use are less clear. They may not be indicated for all febrile conditions because some paradoxically contribute to patient discomfort, interfere with accurately assessing patients receiving antimicrobials, or predispose patients to adverse effects from other medications. The development of more selective fever-relieving agents and their prudent use With attention to possible untoward consequences are important to the future quality of clinical medicine. (C) 2001 by Excerpta Medica, Inc.
引用
收藏
页码:304 / 315
页数:12
相关论文
共 97 条
[41]   EFFECT OF HIGH-DOSE IBUPROFEN IN PATIENTS WITH CYSTIC-FIBROSIS [J].
KONSTAN, MW ;
BYARD, PJ ;
HOPPEL, CL ;
DAVIS, PB .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (13) :848-854
[42]   INHIBITION OF NF-KAPPA-B BY SODIUM-SALICYLATE AND ASPIRIN [J].
KOPP, E ;
GHOSH, S .
SCIENCE, 1994, 265 (5174) :956-959
[43]   Role of cytochrome P-450 in endogenous antipyresis [J].
Kozak, W ;
Kluger, MJ ;
Kozak, A ;
Wachulec, M ;
Dokladny, K .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 2000, 279 (02) :R455-R460
[44]  
Kozak W, 2000, ANN NY ACAD SCI, V917, P121
[45]  
Krump E, 1999, ADV EXP MED BIOL, V447, P107
[46]   Inflammatory molecule release by β-amyloid-treated T98G astrocytoma cells:: role of prostaglandins and modulation by paracetamol [J].
Landolfi, C ;
Soldo, L ;
Polenzani, L ;
Apicella, C ;
de Joannon, AC ;
Coletta, I ;
Di Cesare, F ;
Brufani, M ;
Pinza, M ;
Milanese, C .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 360 (01) :55-64
[47]   An antipyretic role for interleukin-10 in LPS fever in mice [J].
Leon, LR ;
Kozak, W ;
Rudolph, K ;
Kluger, MJ .
AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY, 1999, 276 (01) :R81-R89
[48]   The febrile response to lipopolysaccharide is blocked in cyclooxygenase-2-/-, but not in cyclooxygenase-1-/- mice [J].
Li, S ;
Wang, Y ;
Matsumura, K ;
Ballou, LR ;
Morham, SG ;
Blatteis, CM .
BRAIN RESEARCH, 1999, 825 (1-2) :86-94
[49]   Cytokines and fever - Mechanisms and sites of action [J].
Luheshi, GN .
MOLECULAR MECHANISMS OF FEVER, 1998, 856 :83-89
[50]   Benefits and risks of antipyretic therapy [J].
Mackowiak, PA ;
Plaisance, KI .
MOLECULAR MECHANISMS OF FEVER, 1998, 856 :214-223